We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel MRI Contrast Agent Swiftly Eliminated from Body

By MedImaging International staff writers
Posted on 12 Jan 2021
Print article
Image: MRI manganese-based contrast agents are as efficient as gadolinium, but less toxic (Photo courtesy of Eric Gale/ MGH)
Image: MRI manganese-based contrast agents are as efficient as gadolinium, but less toxic (Photo courtesy of Eric Gale/ MGH)
A new study suggests that a manganese (Mn) based magnetic resonance imaging (MRI) contrast agent could soon replace gadolinium-based contrast agents (GBCAs) as a non-toxic alternative.

Researchers at Massachusetts General Hospital (MGH; Boston, USA) and Harvard Medical School (HMS; Boston, MA, USA) conducted a study to compare the new contrast agent, Mn-PyC3A, to the older Mn-based contrast agent mangafodipir (Mn-DPDP), and to the GBCA gadoterate (Gd-DOTA). For the study, the researchers used simultaneous positron emission tomography (PET) and MRI (PET-MRI) to compare pharmacokinetics, in-vivo biodistribution, and whole-body elimination in a rat model.

The results revealed that while both Mn-PyC3A and Mn-DPDP are eliminated via mixed hepatobiliary and renal routes, a greater fraction of the Mn-PyC3A contrast agent was eliminated by renal filtration. Whole-body PET images showed that Mn-PyC3A was efficiently eliminated, whereas Mn-DPDP was retained throughout the body. The experimental data also showed significantly more efficient whole-body elimination of Mn-PyC3A than Gd-DOTA both one day and one week after injection. The study was published on October 30, 2020, in Investigative Radiology.

“This manganese-based contrast agent does everything a GBCA would do; this is obviously important for patients with chronic kidney disease and other forms of renal insufficiency that might require careful risk/benefit analysis before undergoing a GBCA-enhanced MRI,” said senior author biomedical engineer Eric Gale, PhD, of MGH and HMS, co-inventor of Mn-PyC3A. “But we can also envision giving Mn-PyC3A to any patient requiring a contrast-enhanced MRI. There are patients who require many GBCA-enhanced MRI examinations over the course of years for disease surveillance or screening.”

Efficient elimination of a contrast agent is critical for tissue health. Since Gadolinium is eliminated only from the kidneys, retention from GBCAs can cause nephrogenic systemic fibrosis, and it is also retained in the brain, bones, skin and other organs, even in patients with normal kidney function. Mn-PyC3A, on the other hand, is also eliminated from the liver, compensating for diminished renal function in kidney patients and ensuring a more rapid and complete elimination.

Related Links:
Massachusetts General Hospital
Harvard Medical School



Print article
Sun Nuclear/Gammex
CIRS

Channels

Industry News

view channel
Illustration

Siemens Partners with Epsilon Imaging on EchoInsight Analysis Software with Strain Imaging

Siemens Healthineers (Erlangen, Germany) has entered into a partnership with Epsilon Imaging (Ann Arbor, MI, USA) to offer syngo Dynamics users EchoInsight visualization and analysis with strain imaging.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.